Reason for request
Inclusion
Clinical Benefit
| Substantial |
The actual benefit of TIVICAY in the indication “treatment of Human Immunodeficiency Virus (HIV)-infected adults and adolescents above 12 years of age” is substantial in antiretroviral naïve patients and in experienced patients with prior treatment failure. |
Clinical Added Value
| moderate |
In patients who have no therapeutic options and whose virus is susceptible to dolutegravir :
The Transparency Committee considers that TIVICAY (dolutegravir), in combination with an optimised background regimen, provides a moderate improvement in actual benefit (level III) in terms of immunological and virological efficacy in therapeutic management. |
| minor |
In antiretroviral-naïve or experienced patients whose virus does not have integrase inhibitor (INI) resistance mutations :
The Transparency Committee considers that TIVICAY (dolutegravir) incombination with other antiretrovirals provides a minor improvement in actual benefit (level IV) compared with raltegravir (ISENTRESS) due to having an immunological and virological efficacy that is not inferior to that of raltegravir with a higher genetic barrier to the development of resistance and better ease of use than raltegravir (a single dose versus two daily doses in the case of raltegravir). |
See also
HAS opinions and decisions
05/03/2014
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
V142sHqj2LXP1Vpw
